Hypoxic stress, brain vascular system, and β-amyloid: A primary cell culture study

Nutritional Neuroscience

Volumn 18, Issue 1, 2015, Pages 1-11

  Muche, Abebe ^a   Bürger, Susanne ^a   Arendt, Thomas ^a   Schliebs, Reinhard ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Amyloid precursor protein; Brain vascular endothelial cell; ELISA; Primary cell culture; SU 5416; Tg2576 mouse; VEGF

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN [1-40]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROTEIN TYROSINE KINASE; SEMAXANIB; SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA; SOLUBLE AMYLOID PRECURSOR PROTEIN BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; CULTURE MEDIUM; SECRETASE; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; BRAIN BLOOD VESSEL; BRAIN CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SECRETION (PROCESS); UPREGULATION; WESTERN BLOTTING; ALZHEIMER DISEASE; ANIMAL; BRAIN; BRAIN HYPOXIA; CELL HYPOXIA; CHEMISTRY; CULTURE MEDIUM; ENDOTHELIUM CELL; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PRIMARY CELL CULTURE; PROCEDURES; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; VASCULARIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; CELL HYPOXIA; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; HUMANS; HYPOXIA, BRAIN; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84919422979     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1179/1476830513Z.000000000112     Document Type: Article

References (62)

1. Schliebs R. Alzheimer’s disease. In: Kasabov N, (ed.) Springer handbook of bio-/neuroinformatics. Frankfurt: Springer; 2014.
2. Thathiah A, De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. Nat Rev Neurosci 2011;12:73–87.
3. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer’s disease. Mol Brain 2011;4:3.
4. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 2011;377:1019–31.
5. Honjo K, Black SE, Verhoeff NP. Alzheimer’s disease, cerebro-vascular disease, and the beta-amyloid cascade. Can J Neurol Sci 2012;39:712–28.
6. Mullane K, Williams M. Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 2013;85:289–305.
7. de la Torre JC. The vascular hypothesis of Alzheimer’s disease: bench to bedside and beyond. Neurodegener Dis 2010;7:116–21.
8. Kalaria R. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010;68(Suppl. 2): S74–87.
9. Nicolakakis N, Hamel E. Neurovascular function in Alzheimer’s disease patients and experimental models. J Cereb Blood Flow Metab 2011;31:1354–70.
10. Gahr M, Nowak DA, Connemann BJ, Schonfeldt-Lecuona C. Cerebral amyloidal angiopathy-A disease with implications for neurology and psychiatry. Brain Res 2013;1519:19–30.
11. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol 2009;118:87–102.
12. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 2011;12:723–38.
13. Grinberg LT, Korczyn AD, Heinsen H. Cerebral amyloid angiopathy impact on endothelium. Exp Gerontol 2012;47:838–42.
14. Coma M, Guix FX, Ill-Raga G, Uribesalgo I, Alameda F, Valverde MA, et al. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol Aging 2008;29:969–80.
15. Zhang X, Le W. Pathological role of hypoxia in Alzheimer’s disease. Exp Neurol 2010;223:299–303.
16. Nalivaeva NN, Belyaev ND, Zhuravin IA, Turner AJ. The Alzheimer’s amyloid-degrading peptidase, neprilysin: can we control it? Int J Alzheimers Dis 2012;2012:383796.
17. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006;103: 18727–32.
18. Attems J, Lintner F, Jellinger KA. Amyloid beta peptide 1–42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol 2004;107: 283–91.
19. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 2004;366:80–5.
20. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis 2004;7:75–85.
21. Zand L, Ryu JK, McLarnon JG. Induction of angiogenesis in the beta-amyloid peptide-injected rat hippocampus. Neuroreport 2005;16:129–32.
22. Hayashi H, Nakagami H, Takami Y, Sato N, Saito Y, Nishikawa T, et al. Involvement of gamma-secretase in postnatal angiogen-esis. Biochem Biophys Res Commun 2007;363:584–90.
23. Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, Mullan M. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur J Pharmacol 2005; 514:1–15.
24. Cole SL, Vassar R. Linking vascular disorders and Alzheimer’s disease: potential involvement of BACE1. Neurobiol Aging 2009;30:1535–44.
25. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120:287–96.
26. Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke 2009;40:2601–6.
27. Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM. Vascular beta-amyloid and early astrocyte alterations impair cerebrovas-cular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol 2011;122:293–311.
28. Ciallella JR, Figueiredo H, Smith-Swintosky V, McGillis JP. Thrombin induces surface and intracellular secretion of amyloid precursor protein from human endothelial cells. Thromb Haemost 1999;81:630–7.
29. Ichikawa N, Naora K, Hirano H, Hashimoto M, Masumura S, Iwamoto K. Isolation and primary culture of rat cerebral micro-vascular endothelial cells for studying drug transport in vitro. J Pharmacol Toxicol Methods 1996;36:45–52.
30. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274(5284):99–102.
31. Gordon EL, Danielsson PE, Nguyen TS, Winn HR. A comparison of primary cultures of rat cerebral microvascular endothelial cells to rat aortic endothelial cells. In Vitro Cell Dev Biol 1991; 27A:312–26.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–75.
33. Burger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E, et al. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from trans-genic Tg2576 mouse brain. Int J Dev Neurosci 2009;27:517–23.
34. Burger S, Yafai Y, Bigl M, Wiedemann P, Schliebs R. Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis, on processing of the beta-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice. Int J Dev Neurosci 2010;28:597–604.
35. Webster NJ, Green KN, Peers C, Vaughan PF. Altered processing of amyloid precursor protein in the human neuroblastoma SH-SY5Y by chronic hypoxia. J Neurochem 2002;83:1262–71.
36. Webster NJ, Green KN, Settle VJ, Peers C, Vaughan PF. Altered processing of the amyloid precursor protein and decreased expression of ADAM 10 by chronic hypoxia in SH-SY5Y: no role for the stress-activated JNK and p38 signalling pathways. Brain Res Mol Brain Res 2004;130:161–9.
37. Nural-Guvener HF, Mutlu N, Gaballa MA. BACE1 levels are elevated in congestive heart failure. Neurosci Lett 2013;532: 7–11.
38. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007;282:10873–80.
39. Westmark CJ, Malter JS. The regulation of AbetaPP expression by RNA-binding proteins. Ageing Res Rev 2012;11:450–9.
40. Minopoli G, Passaro F, Aloia L, Carlomagno F, Melillo RM, Santoro M, et al. Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. Neurodegener Dis 2007;4:94–100.
41. Checler F, Dunys J. p53, a pivotal effector of a functional crosstalk linking presenilins and Pen-2. Neurodegener Dis 2012;10: 52–5.
42. McCarthy JV, Twomey C, Wujek P. Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci 2009;66:1534–55.
43. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005;7:134–53.
44. Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging 2009;30:1091–8.
45. Guglielmotto M, Tamagno E, Danni O. Oxidative stress and hypoxia contribute to Alzheimer’s disease pathogenesis: two sides of the same coin. Scientific World J 2009;9:781–91.
46. Li S, Wang W, Wang C, Tang YY. Possible involvement of NO/ NOS signaling in hippocampal amyloid-beta production induced by transient focal cerebral ischemia in aged rats. Neurosci Lett 2010;470:106–10.
47. Apelt J, Bigl M, Wunderlich P, Schliebs R. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci 2004;22:475–84.
48. Endres K, Fahrenholz F. Regulation of alpha-secretase ADAM10 expression and activity. Exp Brain Res 2012;217: 343–52.
49. Lichtenthaler SF. Alpha-secretase cleavage of the amyloid precursor protein: proteolysis regulated by signaling pathways and protein trafficking. Curr Alzheimer Res 2012;9:165–77.
50. Sun X, Bromley-Brits K, Song W. Regulation of beta-site APP-cleaving enzyme 1 gene expression and its role in Alzheimer’s disease. J Neurochem 2012;120(Suppl. 1):62–70.
51. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, et al. Beta-site APP cleaving enzyme up-regu-lation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 2005;92:628–36.
52. Wan XZ, Li B, Li YC, Yang XL, Zhang W, Zhong L, et al. Activation of NMDA receptors upregulates a disintegrin and metalloproteinase 10 via a Wnt/MAPK signaling pathway. J Neurosci 2012;32:3910–6.
53. Shi C, Zheng DD, Fang L, Wu F, Kwong WH, Xu J. Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/ Akt. Biochim Biophys Acta 2012;1820:453–60.
54. Zhang H, Gao Y, Dai Z, Meng T, Tu S, Yan Y. IGF-1 reduces BACE-1 expression in PC12 cells via activation of PI3-K/Akt and MAPK/ERK1/2 signaling pathways. Neurochem Res 2011;36:49–57.
55. Yim SY, Chae KR, Shim SB, Hong JT, Park JY, Lee CY, et al. ERK activation induced by selenium treatment significantly downregulates beta/gamma-secretase activity and Tau phos-phorylation in the transgenic rat overexpressing human seleno-protein M. Int J Mol Med 2009;24:91–6.
56. Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW, Mook-Jung I. ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J 2006;20:157–9.
57. Tamagno E, Guglielmotto M, Giliberto L, Vitali A, Borghi R, Autelli R, et al. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol Aging 2009; 30:1563–73.
58. Zuchner T, Perez-Polo JR, Schliebs R. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. J Neurosci Res 2004;77:250–7.
59. Canet-Aviles RM, Anderton M, Hooper NM, Turner AJ, Vaughan PF. Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(alpha), src-tyrosine kinase and extracellular signal-regulated kinase but not phos-pholipase C. Brain Res Mol Brain Res 2002;102:62–72.
60. Hyman BT, Elvhage TE, Reiter J. Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippo-campal formation in Alzheimer’s disease. Am J Pathol 1994;144: 565–72.
61. Trojanowski JQ, Mawal-Dewan M, Schmidt ML, Martin J, Lee VM. Localization of the mitogen activated protein kinase ERK2 in Alzheimer’s disease neurofibrillary tangles and senile plaque neurites. Brain Res 1993;618:333–7.
62. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, et al. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 1999;10:2411–5.